Mimetogen Pharmaceuticals Inc. Expands Its Board of Directors

Mimetogen Pharmaceuticals Inc. is pleased to announce the appointment of Dr Martin B. Wax to its Board of Directors.  “We are enormously honored that Dr. Wax has agreed to join the board of Mimetogen Pharmaceuticals Inc.,” said Garth Cumberlidge, Chief Executive Officer.  “His extensive experience in ocular drug development adds a new degree of knowledge to our management team and will be of tremendous value in directing our efforts to bring novel solutions to a number of ocular indications including dry eye and glaucoma to market.”

Martin B. Wax M.D. is currently the Chief Medical Officer and Executive Vice-President of R&D at PanOptica, Inc., a private biotechnology company specializing in ophthalmic pharmaceuticals. He was Vice President of R&D and Head of Ophthalmology Discovery Research and Preclinical Sciences at Alcon Laboratories in Ft. Worth, Texas from 2003-2008.  He was responsible for the creation and development of the Alcon pharmaceutical portfolio of compounds for the therapeutic areas of glaucoma, retina, allergy, dry eye and anti-infectives.  He also holds an appointment as a Professor of Ophthalmology and Visual Sciences at the University of Texas Southwestern Medical School in Dallas, Texas and has been selected as one of the “Best Doctors in America” 2005-2008 by his peers.  Dr. Wax received his medical degree from the University of Southern California in Los Angeles. He completed his residency in Ophthalmology at Wills Eye Hospital in Pennsylvania, and was a postdoctoral fellow first in Neuropharmacology and then in Glaucoma at the University of Pennsylvania School of Medicine in Philadelphia.  Before entering industry as the head of Ophthalmology Research at Pharmacia Corporation in 2002, he held the distinguished Research to Prevent Blindness Chair as a Professor of Ophthalmology at Washington University School of Medicine in St. Louis, MO.  He has chaired numerous national and international commercial advisory boards for industry sponsors throughout his academic and industry career.

“The strong science behind Mimetogen's new approach using neurotrophin mimetics for the treatment of dry eye is compelling. This approach represents a significant opportunity not only in the treatment of dry eye, but also for other ocular indications” said Dr. Wax.  “I look forward to helping Mimetogen commercialize these novel therapies and assist patients with these diseases."